Management of Breakthrough Bleeding on Testosterone and Progesterone

Understanding the Condition and Initial Assessment

The American College of Cardiology recommends evaluating endometrial thickness by ultrasound before modifying progesterone therapy, as part of the initial assessment for breakthrough bleeding on testosterone and progesterone 1
Pregnancy testing is mandatory in all reproductive-age individuals with abnormal uterine bleeding, according to the American Heart Association 3, 4

The standard therapeutic dose for a sequential regimen is 200 mg daily for 12-14 days per month, which provides proven endometrial protection while minimizing bleeding complications, as recommended by the American College of Obstetricians and Gynecologists 1
A continuous regimen of 100 mg daily for 25 days per month provides adequate endometrial protection with continuous coverage, according to the American College of Obstetricians and Gynecologists 1

Switching from 600 mg daily to 200 mg daily for 12-14 days per month (sequential regimen) provides proven endometrial protection while minimizing bleeding complications, as recommended by the American College of Obstetricians and Gynecologists 1, 2
Waiting 3 months before making further changes allows for the resolution of breakthrough bleeding, which typically resolves within the first 3 months of proper progesterone therapy, according to the American College of Obstetricians and Gynecologists 1, 2
Increasing progesterone to 300-400 mg daily for 10 days can be used for more resistant cases, as recommended by the American College of Obstetricians and Gynecologists 1
Switching to a continuous regimen (100 mg daily) can be considered if the patient prefers to avoid withdrawal bleeding, according to the American College of Obstetricians and Gynecologists 1, 2
Considering a levonorgestrel IUD (20 μg/day) reduces menstrual blood loss by 71-95% with minimal systemic absorption, as recommended by the American Heart Association 3, 4

Avoid inadequate duration of progesterone therapy, as it must be given for at least 12 days per month in sequential regimens to provide endometrial protection, according to the American College of Obstetricians and Gynecologists 1, 2
Premature treatment changes should be avoided, and a full 3 months should be waited before declaring a regimen ineffective, as recommended by the American College of Obstetricians and Gynecologists 1, 2
Using excessive doses above 400 mg daily is not evidence-based and may worsen bleeding, according to the American College of Obstetricians and Gynecologists 1
NSAIDs and tranexamic acid should be generally avoided in patients with cardiovascular concerns, though can be used short-term (5-7 days) if medically appropriate, as recommended by the American Heart Association 3, 1

Reassessing at 3 months to evaluate bleeding pattern and treatment response is recommended, according to the American College of Obstetricians and Gynecologists 1, 2
Repeating endometrial ultrasound if bleeding persists or worsens is recommended, according to the American College of Obstetricians and Gynecologists 1